Myriad Genetics MYGN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $200.4M+2.3% | $209.8M-0.4% | $205.7M-3.6% | $213.1M+0.8% | $195.9M-3.1% | ||
| $62.8M+1.8% | $63M+5.5% | $61.9M-2.5% | $61.3M-4.8% | $61.7M-4.5% | ||
| $137.6M+2.5% | $146.8M-2.7% | $143.8M-4.0% | $151.8M+3.2% | $134.2M-2.5% | ||
| 68.7%+0.2pp | 70%-1.7pp | 69.9%-0.3pp | 71.2%+1.7pp | 68.5%+0.5pp | ||
| $27.1M-1.5% | $25.5M-20.8% | $28.2M-1.1% | $25.6M-5.5% | $27.5M+10.4% | ||
| $73.6M+6.4% | $68.7M-4.6% | $71M+1.6% | $71.9M-1.2% | $69.2M-0.3% | ||
| $62.2M-6.5% | $55.6M-13.1% | $67.9M-1.9% | $66.8M-7.4% | $66.5M-6.6% | ||
| $168.3M+3.1% | $152.5M-19.7% | $167.1M-1.6% | $481M+162% | $163.2M-1.4% | ||
| $168.3M+3.1% | $152.5M-19.7% | $167.1M-1.6% | $481M+162% | $163.2M-1.4% | ||
| -$30.7M-5.9% | -$5.7M+85.4% | -$23.3M-16.5% | -$329.2M-802% | -$29M-3.9% | ||
| -15.3%-0.5pp | -2.7%+15.8pp | -11.3%-2.0pp | -154.5%-137pp | -14.8%-1.0pp | ||
| $4.1M+413% | $4.4M+529% | $3.8M+375% | $1.5M+87.5% | $800K+60.0% | ||
| $700K+133% | $800K+167% | $500K+25.0% | $200K-50.0% | $300K-50.0% | ||
| -$3.4M-750% | -$3.2M-3,100% | -$2.9M-142% | -$1.4M-100% | -$400K-120% | ||
| -$34.1M-16.0% | -$8.9M+77.2% | -$26.2M-23.6% | -$330.6M-789% | -$29.4M-13.5% | ||
| $0+100% | -$1M-129% | $1.2M+33.3% | -$100K+80.0% | -$29.3M-29,400% | ||
| -$34.1M-34,000% | -$7.9M+81.4% | -$27.4M-24.0% | -$330.5M-801% | -$100K+99.6% | ||
| -17%-17.0pp | -3.8%+16.4pp | -13.3%-3.0pp | -155.1%-138pp | -0.1%+12.8pp | ||
| -$0.36— | -$0.07+85.1% | -$0.29-20.8% | -$3.57-771% | $0.00+100% | ||
| -$0.36— | -$0.07+85.1% | -$0.29-20.8% | -$3.57-771% | $0.00+100% | ||
| 93.7M+2.5% | 92.6M+2.2% | 93.1M+2.4% | 92.5M+2.1% | 91.4M+1.7% | ||
| 93.7M+2.5% | 92.6M+2.2% | 93.1M+2.4% | 92.5M+2.1% | 91.4M+1.7% | ||
| —— | $0+100% | $0+100% | $0+100% | $0+100% | ||
| $0-100% | $400K+33.3% | $400K+150% | -$100K+66.7% | $100K-94.7% | ||
| $200.4M+2.3% | $209.8M-0.4% | $205.7M-3.6% | $213.1M+0.8% | $195.9M-3.1% | ||
| $6.5M-31.6% | $2.8M-74.3% | $12.2M-1.6% | $10.7M-26.2% | $9.5M-20.8% | ||
| -$30.7M-5.9% | -$5.7M+85.4% | -$23.3M-16.5% | -$329.2M-802% | -$29M-3.9% | ||
| -$18.2M-24.7% | $6.9M+129% | -$10.7M-143% | -$315.1M-1,372% | -$14.6M-19.7% | ||
| -$18.2M-24.7% | $6.9M+129% | -$10.7M-143% | -$315.1M-1,372% | -$14.6M-19.7% | ||
| -9.1%-1.6pp | 3.3%+14.8pp | -5.2%-3.1pp | -147.9%-138pp | -7.5%-1.4pp | ||
| -$30.7M-5.9% | -$5.7M+85.4% | -$23.3M-16.5% | -$329.2M-802% | -$29M-3.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Myriad Genetics's revenue?
- Myriad Genetics (MYGN) generated $829.0M in revenue over the trailing twelve months, down 0.3% year over year.
- Is Myriad Genetics profitable?
- Myriad Genetics is not currently profitable: it reported a net loss of $399.9M over the trailing twelve months, a -48.2% net margin.
- What are Myriad Genetics's profit margins?
- Gross margin is 70.0% and operating margin is -46.9%, with a -48.2% net margin.
- What is Myriad Genetics's earnings per share?
- Myriad Genetics's diluted EPS over the trailing twelve months is $-4.29.
- Where does Myriad Genetics's income statement data come from?
- Every line is extracted from Myriad Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
